HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
3,195.00
-75.00 (-2.29%)
At close: Dec 10, 2025
HLB Therapeutics Revenue
HLB Therapeutics had revenue of 16.06B KRW in the quarter ending September 30, 2025, with 14.32% growth. This brings the company's revenue in the last twelve months to 63.25B, up 16.82% year-over-year. In the year 2024, HLB Therapeutics had annual revenue of 54.93B with 4.45% growth.
Revenue (ttm)
63.25B
Revenue Growth
+16.82%
P/S Ratio
4.34
Revenue / Employee
1.29B
Employees
49
Market Cap
274.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.93B | 2.34B | 4.45% |
| Dec 31, 2023 | 52.59B | 10.19B | 24.03% |
| Dec 31, 2022 | 42.40B | -1.18B | -2.72% |
| Dec 31, 2021 | 43.59B | 656.63M | 1.53% |
| Dec 31, 2020 | 42.93B | -16.04B | -27.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |